Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT ID: NCT02486718
Last Updated: 2026-01-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
1280 participants
INTERVENTIONAL
2015-10-31
2027-12-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
NCT02409342
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
NCT03191786
A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
NCT04611776
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
NCT03456063
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
NCT02813785
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atezolizumab
Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
Atezolizumab
Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
Cisplatin
Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
Vinorelbine
Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Docetaxel
Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Gemcitabine
Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Pemetrexed
Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Best Supportive Care
Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed \[non-squamous cell NSCLC only\]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
Cisplatin
Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
Vinorelbine
Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Docetaxel
Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Gemcitabine
Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Pemetrexed
Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
Cisplatin
Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
Vinorelbine
Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Docetaxel
Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Gemcitabine
Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Pemetrexed
Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological or cytological diagnosis of Stage IB (tumors greater than or equal to \[\>/=\] 4 centimeters \[cm\])-IIIA (T2-3 N0, T1-3 N1, T1-3 N2, T4 N0-1) NSCLC (per the Union Internationale Contre le Cancer staging system (UICC)/American Joint Committee on Cancer staging system (AJCC) staging system, 7th edition; Detterbeck et al. 2009)
* Participants must have had complete resection of NSCLC 4-12 weeks (\>/=28 days and less than or equal to \[\</=\] 84 days) prior to enrollment and must be adequately recovered from surgery
* If mediastinoscopy was not performed preoperatively, it is required that, at a minimum, mediastinal lymph node systematic sampling will have occurred. Systematic sampling is defined as removal of at least one representative lymph node at specified levels. MLND entails resection of all lymph nodes at those same levels. For a right thoracotomy, sampling or MLND is required at levels 4 and 7 and for a left thoracotomy, levels 5 and/or 6 and 7. Exceptions will be granted if there is clear documentation in the operative report or in a separately submitted addendum by the surgeon of exploration of the required lymph node areas, the participant will be considered eligible if no lymph nodes are found in those areas; if participants have documented N2 disease in one level (per the UICC/AJCC staging system, 7th edition; Detterbeck et al. 2009), not all levels need to be sampled; if the preoperative staging imaging results (contrast computed tomography \[CT\] and positron emission tomography \[PET\] scans) do not suggest evidence of disease in the mediastinum, the participant will be considered eligible if N2 nodal sampling is not performed per surgeon's decision
* Eligible to receive a cisplatin-based chemotherapy regimen
* Adequate hematologic and end-organ function
* Women who are not postmenopausal (\>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of cisplatin-based chemotherapy
Exclusion Criteria
* Pregnant and lactating women
* Treatment with prior systemic chemotherapy: Chemotherapy for early stage of malignancy with curative intent, provided that the last dose received was more than 5 years prior to enrollment and low-dose chemotherapy for non-malignant conditions may be allowed upon approval by the Medical Monitor
* Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years before enrollment
* Treatment with any other investigational agent with therapeutic intent within 28 days prior to enrollment
* Participants with hearing impairment
* Known sensitivity to any component of the chemotherapy regimen the participant will be assigned to, or to mannitol
* Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti programmed death ligand 1 (PD-L1) therapeutic antibodies
* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS greater than \[\>\] 90 percent \[%\]) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)
* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
* History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
* Positive test for human immunodeficiency virus (HIV)
* Participants with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening) or hepatitis C
* Active tuberculosis
* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within the previous 3 months, unstable arrhythmias, or unstable angina
* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
* Prior allogeneic bone marrow transplantation or solid organ transplant
* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
* Known tumor PD-L1 expression status as determined by an immunohistochemistry (IHC) assay from other clinical studies (e.g., participants whose PD-L1 expression status was determined during screening for entry into a study with anti-PD-1 or anti-PD-L1 antibodies but were not eligible are excluded)
Specific Exclusions for Pemetrexed Treatment
\- Participants with squamous cell histology
* Signs or symptoms of infection within 14 days prior to randomization (severe infection within 28 days prior to randomization), including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
* Received therapeutic oral or intravenous (IV) antibiotics within 14 days prior to randomization
* Major surgical procedure within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
* Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live attenuated vaccine will be required during the study
* Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to randomization: Prior treatment with cancer vaccines is allowed
* Treatment with systemic corticosteroids or other immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-TNF\] agents) within 14 days prior to randomization
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Highlands Oncology Group
Fayetteville, Arkansas, United States
California Cancer Associates for Research & Excellence, Inc.
Encinitas, California, United States
Compassionate Cancer Care Medical Group, Inc
Fountain Valley, California, United States
University of California Los Angeles
Los Angeles, California, United States
Kaiser Permanente
Vallejo, California, United States
Kaiser Permanente - Walnut Creek
Walnut Creek, California, United States
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, United States
Lynn Cancer Institute - West
Boca Raton, Florida, United States
University of Miami School of Medicine - Sylvester at Deerfield
Deerfield Beach, Florida, United States
SCRI Florida Cancer Specialists North
St. Petersburg, Florida, United States
Lewis Hall Singletary Oncology Center
Thomasville, Georgia, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Illinois Cancer Care
Peoria, Illinois, United States
Norton Cancer Institute
Louisville, Kentucky, United States
St. Luke's Cancer Institute
Kansas City, Missouri, United States
Hematology Oncology Associates of Northern New Jersey
Florham Park, New Jersey, United States
Saint Barnabas Medical Center
Livingston, New Jersey, United States
Valley Hospital
Paramus, New Jersey, United States
Overlook Medical Center
Summit, New Jersey, United States
Clinical Research Alliance
Lake Success, New York, United States
Weill Cornell Medical College
New York, New York, United States
Presbyterian Hospital
Charlotte, North Carolina, United States
University of Cincinnati
Cincinnati, Ohio, United States
Oncology Hematology Care - SCRI
Cincinnati, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
University Oncology Associates
Chattanooga, Tennessee, United States
Houston Methodist Cancer Center
Houston, Texas, United States
Wellmont Medical Associates
Bristol, Virginia, United States
Hematology Oncology Associates of Fredericksburg, Inc.
Fredericksburg, Virginia, United States
MultiCare Regional Cancer Center - Auburn
Auburn, Washington, United States
Providence Everett Med Ctr
Everett, Washington, United States
Swedish Medical Center
Seattle, Washington, United States
Townsville Hospital
Douglas, Queensland, Australia
Cabrini Hospital Malvern
Malvern, Victoria, Australia
Cliniques Universitaires St-Luc
Brussels, , Belgium
CHU de Liège (Sart Tilman)
Liège, , Belgium
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Beijing, , China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, , China
Zhejiang Cancer Hospital
Hangzhou, , China
Anhui Province Cancer Hospital
Hefei, , China
Shanghai Chest Hospital
Shanghai, , China
Shanghai Pulmonary Hospital
Shanghai, , China
Liaoning Provincial Cancer Hospital
Shengyang, , China
First Hospital of China Medical University
Shenyang, , China
First Affiliated Hospital of Soochow University
Suzhou, , China
Centre Hospitalier de Mont de Marsan - Hopital Layne
Mont-de-Marsan, , France
Clinique Clémentville
Montpellier, , France
Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque
Montpellier, , France
Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique
Nantes, , France
Centre Hospitalier Regional Sud Reunion
Saint-Pierre, , France
Centre Hospitalier de Saint-Quentin
Saint-Quentin, , France
Hopital d Instruction des Armees de Sainte Anne
Toulon, , France
Ev.Krankenhaus Bielefeld gGmbH
Bielefeld, North Rhine-Westphalia, Germany
Evang. Lungenklinik Berlin Klinik für Pneumologie
Berlin, , Germany
Stadtisches Klinikum Braunschweig
Braunschweig, , Germany
Klinikum Chemnitz gGmbH
Chemnitz, , Germany
Krankenhaus Nordwest
Frankfurt am Main, , Germany
LungenClinic Grosshansdorf GmbH
Großhansdorf, , Germany
Lungenklinik Hemer
Hemer, , Germany
Universität Des Saarlandes
Homburg, , Germany
Fachklinik für Lungenerkrankungen
Immenhausen, , Germany
Vincentius-Diakonissen-Kliniken gAG
Karlsruhe, , Germany
Katholisches Klinikum Marienhof
Koblenz Am Rhein, , Germany
Klinikum Bogenhausen
München, , Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, , Germany
Pius-Hospital Oldenburg
Oldenburg, , Germany
Krankenhaus Barmherzige Bruder Regensburg
Regensburg, , Germany
Prince of Wales Hosp
Shatin, , Hong Kong
University of Pecs, I st Dept of Internal Medicine
Pécs, , Hungary
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int.
Szolnok, , Hungary
Rambam Medical Center
Haifa, , Israel
Edith Wolfson Medical Center
Holon, , Israel
Meir Medical Center
Kfar Saba, , Israel
Tel Aviv Sourasky Medical Ctr
Tel Aviv, , Israel
Chaim Sheba Medical Center
Tel Litwinsky, , Israel
Ospedale Clinicizzato SS Annunziata
Chieti, Abruzzo, Italy
Azienda per l'Assistenza Sanitaria N° 5 - Friuli Occidentale
Pordenone, Friuli Venezia Giulia, Italy
Policlinico Universitario Campus Biomedico Di Roma
Rome, Lazio, Italy
Asst Papa Giovanni XXIII
Bergamo, Lombardy, Italy
ASST Spedali Civili di Brescia
Brescia, Lombardy, Italy
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
Orbassano, Piedmont, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Turin, Piedmont, Italy
Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi
Catania, Sicily, Italy
Ospedale Santa Chiara
Trento, Trentino-Alto Adige, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, Italy
Ospedale Silvestrini
Perugia, Umbria, Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Veneto, Italy
Aichi Cancer Center Hospital
Aichi, , Japan
Hyogo Cancer Center
Akashi, , Japan
Juntendo University Hospital
Bunkyō City, , Japan
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
Bunkyō City, , Japan
National Cancer Center Hospital
Chūō, , Japan
Kyushu University Hospital
Fukuoka, , Japan
Hiroshima University Hospital
Hiroshima, , Japan
Saitama Cancer Center
Kitaadachi-gun, , Japan
Hospital of the University of Occupational and Environmental Health,Japan
Kitakyushu-shi, , Japan
Kumamoto University Hospital
Kumamoto, , Japan
Kyoto University Hospital
Kyoto, , Japan
Shikoku Cancer Center
Matsuyama, , Japan
Kyorin University Hospital
Mitaka-shi, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Okayama University Hospital
Okayama, , Japan
National Hospital Organization Hokkaido Cancer Center
Sapporo, , Japan
Toranomon Hospital
Tokyo, , Japan
Tokyo Medical University Hospital
Tokyo, , Japan
Kanagawa Cancer Center
Yokohama-shi, Asahi-ku, , Japan
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, North Brabant, Netherlands
St. Antonius Ziekenhuis Nieuwegein
Nieuwegein, , Netherlands
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
Otwock, , Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
Poznan, , Poland
Centro Hospitalar E Universitário de Coimbra EPE
Coimbra, , Portugal
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe
Porto, , Portugal
Hospital de Sao Joao
Porto, , Portugal
Oncology Center Sf. Nectarie
Craiova, , Romania
Principal Military Clinical Hospital n.a. N.N. Burdenko
Moscow, Moscow Oblast, Russia
Leningrad Regional Clinical Hospital
Saint Petersburg, Sankt-Peterburg, Russia
GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)
Saint Petersburg, Sankt-Peterburg, Russia
Scientific Research Institute of Oncology n.a. N.N. Petrov
Saint Petersburg, Sankt-Peterburg, Russia
City Clinical Hospital #1
Novosibirsk, , Russia
Volgograd Regional Clinical Oncology Dispensary
Volgograd, , Russia
Regional Clinical Oncology Hospital
Yaroslavl, , Russia
Chonnam National University Hwasun Hospital
Jeonnam, , South Korea
The Catholic University of Korea St. Vincent's Hospital
Suwon, , South Korea
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Consorcio Hospitalario Provincial de Castellon
Castellon, Castellon, Spain
Hospital Universitario Virgen de La Arrixaca
El Palmar, Murcia, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Hospital del Mar
Barcelona, , Spain
Hospital Santa Creu i Sant Pau
Barcelona, , Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, , Spain
C.H. Regional Reina Sofia
Córdoba, , Spain
Complejo Hospitalario de Jaen
Jaén, , Spain
Hospital Lucus Augusti
Lugo, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Universitario HM Sanchinarro-CIOCC
Madrid, , Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, , Spain
Hosp Clinico Univ Lozano Blesa
Zaragoza, , Spain
Changhua Christian Hospital
Changhua, , Taiwan
Chang Gung Memorial Hospital Chiayi
Putzui City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Medical Foundation Linkou Branch
Taoyuan, , Taiwan
MI Dnipropetrovsk City Multifield Clinical Hospital 4 of Dnipropetrovsk Regional Council
Dnipropetrovsk, Katerynoslav Governorate, Ukraine
Communal Non profit Enterprise Regional Center of Oncology
Kharkiv, Kharkiv Governorate, Ukraine
Municipal Institution Odesa Regional Oncology Dispensary
Odesa, KIEV Governorate, Ukraine
Municipal Institution SubCarpathian ClinicalOncological Centre
Ivano-Frankivsk, Poltava Governorate, Ukraine
Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council
Vinnytsia, Vinnytsia Oblast, Ukraine
CE Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council
Kryvyi Rih, , Ukraine
Kyiv City Clinical Oncological Center
Kyiv, , Ukraine
Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary
Sumy, , Ukraine
MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology
Zaporizhzhya, , Ukraine
Colchester General Hospital
Colchester, Essex, , United Kingdom
St Bartholomew's Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Okada M, Sugawara S, Watanabe Y, Saito H, Chen-Yoshikawa TF, Goto Y, Nishio W, Nakagawa S, Hayashi M, Kenmotsu H. IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer. Cancer Sci. 2025 Dec 19. doi: 10.1111/cas.70297. Online ahead of print.
Felip E, Altorki N, Zhou C, Vallieres E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study Investigators. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. J Clin Oncol. 2025 Jul 20;43(21):2343-2349. doi: 10.1200/JCO-24-01681. Epub 2025 May 30.
Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, Reck M, Liersch R, Kryzhanivska A, Oizumi S, Tanaka H, Hamm J, McCune SL, Bennett E, Gitlitz B, McNally V, Ballinger M, McCleland M, Zou W, Das Thakur M, Novello S. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. J Immunother Cancer. 2023 Oct;11(10):e007047. doi: 10.1136/jitc-2023-007047.
Felip E, Altorki N, Zhou C, Vallieres E, Martinez-Marti A, Rittmeyer A, Chella A, Reck M, Goloborodko O, Huang M, Belleli R, McNally V, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023 Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17.
Mohindra NA, Patel JD. Top advances in lung cancer, 2021. Cancer. 2022 Oct 1;128(19):3434-3437. doi: 10.1002/cncr.34406. Epub 2022 Aug 10.
Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-003205-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2023-505981-26-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
GO29527
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.